| 產(chǎn)品描述： | NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor. |
| 靶點(diǎn)： |
P-glycoprotein;Nrf2 |
| 體內(nèi)研究： |
Both saline alone and NSC23925 alone treated tumors grow progressively. The usage of NSC23925 in paclitaxel chemotherapy significantly prolongs anticancer efficacy of paclitaxel |
| 參考文獻(xiàn)： |
1. Yang X, et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer. 2015 Oct 15;137(8):2029-39. 2. Duan Z, et al. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One. 2009 Oct 12;4(10):e7415. |
| 溶解性： |
Soluble in DMSO、H2O |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.87 ml |
14.35 ml |
28.699 ml |
| 5 mM |
0.574 ml |
2.87 ml |
5.74 ml |
| 10 mM |
0.287 ml |
1.435 ml |
2.87 ml |
| 50 mM |
0.057 ml |
0.287 ml |
0.574 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京